Top 10 Pramipexole (Mirapex) Generic Manufacturers in Brazil
The Brazilian pharmaceutical market has been witnessing significant growth, particularly in the generics sector, which accounted for approximately 34% of the total pharmaceutical sales in 2021. Pramipexole, marketed under the brand name Mirapex, is a critical medication used primarily in the treatment of Parkinson’s disease and Restless Legs Syndrome (RLS). In Brazil, the increasing prevalence of these conditions has driven demand for cost-effective generics, with the Brazilian generic drug market expected to reach USD 7 billion by 2025. This report outlines the top 10 manufacturers of Pramipexole generics in Brazil, showcasing their performance and market presence.
1. EMS Sigma Pharma
EMS Sigma Pharma is one of Brazil’s largest pharmaceutical manufacturers, specializing in generics. The company holds a significant market share of approximately 8% in the Brazilian generics sector. EMS has been a key player in the production of Pramipexole, with an estimated production volume of over 2 million units per year.
2. Aché Laboratórios Farmacêuticos
Aché is renowned for its robust portfolio of generic drugs, including Pramipexole. The company has a market share of around 7% in the generics segment. Aché’s production capacity is impressive, with over 1.5 million units produced annually, catering to both domestic and international markets.
3. Hypera Pharma
Hypera Pharma, one of Brazil’s leading pharmaceutical companies, has a diverse generics portfolio. The company commands about 5% of the generics market and produces over 1 million units of Pramipexole generics each year. Hypera’s strategic investments in R&D contribute to its competitive edge in the generics space.
4. Eurofarma
Eurofarma is recognized for its commitment to quality and innovation in pharmaceuticals. With a market share of approximately 4.5%, Eurofarma produces around 800,000 units of Pramipexole generics annually, making it a significant player in the Brazilian market.
5. Medley Farmacêutica
Medley, a subsidiary of the Sanofi Group, holds a market share of 4% in Brazil’s generics industry. The company produces nearly 600,000 units of Pramipexole generics each year, positioning itself as a reliable supplier in the Brazilian pharmaceutical landscape.
6. Prati-Donaduzzi
Prati-Donaduzzi is a prominent player in the Brazilian generics market with a market share of 3.5%. The company has a production capacity of around 500,000 units of Pramipexole generics annually, focusing on affordability and accessibility for patients.
7. Farmacore
Farmacore has carved a niche in the generics sector with a focus on specialized medications. Holding a market share of about 3%, the company produces approximately 400,000 units of Pramipexole generics each year, meeting the growing demand in Brazil.
8. Laboratório Teuto
Laboratório Teuto is a significant manufacturer of generics in Brazil, with a market share of 2.5%. The company has an annual production capacity of 350,000 units of Pramipexole, contributing to the overall accessibility of essential medications in the Brazilian market.
9. Farmácias Pague Menos
Farmácias Pague Menos, while primarily a retail pharmacy chain, has ventured into generic manufacturing. It holds a market share of approximately 2% and produces around 300,000 units of Pramipexole generics annually, catering to a large customer base across Brazil.
10. Laboratório Bronstein
Laboratório Bronstein specializes in the production of generics and has a smaller but significant market share of around 1.5%. The company produces about 200,000 units of Pramipexole generics per year, helping to broaden the availability of this essential medication.
Insights
The Brazilian market for Pramipexole generics reflects broader trends in the global pharmaceutical industry, characterized by a growing preference for cost-effective alternatives to branded drugs. The generics sector is projected to experience a compound annual growth rate (CAGR) of 8% from 2023 to 2028, driven by demographic shifts and an increasing prevalence of chronic diseases. Furthermore, the Brazilian government’s support for generic medications is expected to bolster production and accessibility, ensuring that patients receive necessary treatments without prohibitive costs. As manufacturers continue to innovate and expand their capabilities, the future of Pramipexole generics in Brazil appears promising, with the market poised for continued growth.
Related Analysis: View Previous Industry Report
